Blood online
Home About Blood Authors Subscriptions Permission Advertising Public Access contact us
 

 
Advanced
Current Issue
First Edition
Future Articles
Archives
Submit to Blood
Search
American Society of Hematology
Meeting Abstracts
Email Alerts
Blood, 30 July 2009, Vol. 114, No. 5, pp. 1038-1045.
Prepublished online as a Blood First Edition Paper on June 3, 2009; DOI 10.1182/blood-2008-12-192039.


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Supplemental Appendices and Tables
Right arrow All Versions of this Article:
blood-2008-12-192039v1
114/5/1038    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Right arrow Rights and Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Google Scholar
Right arrow Articles by Tosello, V.
Right arrow Articles by Ferrando, A. A.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tosello, V.
Right arrow Articles by Ferrando, A. A.
Related Collections
Right arrow Lymphoid Neoplasia
Right arrow Clinical Trials and Observations
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

arrow to previous article Previous Article  |  Table of Contents  |  Next Article next article arrow

LYMPHOID NEOPLASIA

WT1 mutations in T-ALL

Valeria Tosello1, Marc R. Mansour2, Kelly Barnes1, Maddalena Paganin3, Maria Luisa Sulis1,4, Sarah Jenkinson2, Christopher G. Allen2, Rosemary E. Gale2, David C. Linch2, Teresa Palomero1,5, Pedro Real1,6, Vundavalli Murty1, Xiaopan Yao7, Susan M. Richards8, Anthony Goldstone9, Jacob Rowe10, Giuseppe Basso3, Peter H. Wiernik11,12, Elisabeth Paietta11,12, Rob Pieters13,14, Martin Horstmann15,16, Jules P. P. Meijerink13, and Adolfo A. Ferrando1,4,5

1 Institute for Cancer Genetics, Columbia University, New York, NY; 2 Cancer Institute, Department of Haematology, University College London, London, United Kingdom; 3 Hemato-Oncology Laboratory, Department of Pediatrics, University of Padua, Padua, Italy; Departments of 4 Pediatrics and 5 Pathology, Columbia University Medical Center, New York, NY; 6 Andalusian Stem Cell Bank, Centro de Investigacion Biomedica, Granada, Spain; 7 Department of Biostatistics & Computational Biology, Dana-Farber Cancer Institute, Boston, MA; 8 Clinical Trial Service Unit, Oxford, United Kingdom; 9 University College London Hospitals, London, United Kingdom; 10 Rambam Medical Center and Technion, Israel Institute of Technology, Haifa, Israel; 11 Montefiore Medical Center North, Bronx, NY; 12 New York Medical College, New York, NY; 13 Department of Pediatric Oncology/Hematology, Erasmus MC–Sophia Children's Hospital, Rotterdam, The Netherlands; 14 Dutch Childhood Oncology Group, The Hague, The Netherlands; 15 Clinic for Pediatric Hematology and Oncology, University Hospital Hamburg-Eppendorf, Hamburg, Germany; and 16 German Cooperative Study Group for Childhood Acute Lymphoblastic Leukemia, Hamburg, Germany

The molecular mechanisms involved in disease progression and relapse in T-cell acute lymphoblastic leukemia (T-ALL) are poorly understood. We used single nucleotide polymorphism array analysis to analyze paired diagnostic and relapsed T-ALL samples to identify recurrent genetic alterations in T-ALL. This analysis showed that diagnosis and relapsed cases have common genetic alterations, but also that relapsed samples frequently lose chromosomal markers present at diagnosis, suggesting that relapsed T-ALL emerges from an ancestral clone different from the major leukemic population at diagnosis. In addition, we identified deletions and associated mutations in the WT1 tumor suppressor gene in 2 of 9 samples. Subsequent analysis showed WT1 mutations in 28 of 211 (13.2%) of pediatric and 10 of 85 (11.7%) of adult T-ALL cases. WT1 mutations present in T-ALL are predominantly heterozygous frameshift mutations resulting in truncation of the C-terminal zinc finger domains of this transcription factor. WT1 mutations are most prominently found in T-ALL cases with aberrant rearrangements of the oncogenic TLX1, TLX3, and HOXA transcription factor oncogenes. Survival analysis demonstrated that WT1 mutations do not confer adverse prognosis in pediatric and adult T-ALL. Overall, these results identify the presence of WT1 mutations as a recurrent genetic alteration in T-ALL.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
haematolHome page
C. G. Mullighan
Mutations of NOTCH1, FBXW7, and prognosis in T-lineage acute lymphoblastic leukemia
Haematologica, October 1, 2009; 94(10): 1338 - 1340.
[Full Text] [PDF]



 click for free articles
home about blood authors subscriptions permissions advertising public access contact us
  Copyright © 2009 by American Society of Hematology         Online ISSN: 1528-0020